RU2720148C9 - Способ обнаружения солидной злокачественной опухоли - Google Patents

Способ обнаружения солидной злокачественной опухоли Download PDF

Info

Publication number
RU2720148C9
RU2720148C9 RU2016139491A RU2016139491A RU2720148C9 RU 2720148 C9 RU2720148 C9 RU 2720148C9 RU 2016139491 A RU2016139491 A RU 2016139491A RU 2016139491 A RU2016139491 A RU 2016139491A RU 2720148 C9 RU2720148 C9 RU 2720148C9
Authority
RU
Russia
Prior art keywords
biomarker
psa
time point
risk
subject
Prior art date
Application number
RU2016139491A
Other languages
English (en)
Russian (ru)
Other versions
RU2016139491A (ru
RU2720148C2 (ru
RU2016139491A3 (enExample
Inventor
Хенрик ГРЕНБЕРГ
Original Assignee
Пхадиа Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пхадиа Аб filed Critical Пхадиа Аб
Publication of RU2016139491A publication Critical patent/RU2016139491A/ru
Publication of RU2016139491A3 publication Critical patent/RU2016139491A3/ru
Publication of RU2720148C2 publication Critical patent/RU2720148C2/ru
Application granted granted Critical
Publication of RU2720148C9 publication Critical patent/RU2720148C9/ru

Links

Images

Classifications

    • G01N33/575—
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57565—
    • G01N33/5758—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
RU2016139491A 2014-03-11 2015-03-11 Способ обнаружения солидной злокачественной опухоли RU2720148C9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450274 2014-03-11
SE1450274-4 2014-03-11
SE1450420-3 2014-04-04
SE1450420 2014-04-04
PCT/SE2015/050272 WO2015137870A1 (en) 2014-03-11 2015-03-11 Method for detecting a solid tumor cancer

Publications (4)

Publication Number Publication Date
RU2016139491A RU2016139491A (ru) 2018-04-16
RU2016139491A3 RU2016139491A3 (enExample) 2018-10-15
RU2720148C2 RU2720148C2 (ru) 2020-04-24
RU2720148C9 true RU2720148C9 (ru) 2020-09-28

Family

ID=52829276

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016139491A RU2720148C9 (ru) 2014-03-11 2015-03-11 Способ обнаружения солидной злокачественной опухоли

Country Status (9)

Country Link
US (1) US10451626B2 (enExample)
EP (2) EP3117216B1 (enExample)
JP (1) JP6625061B2 (enExample)
AU (2) AU2015230017B2 (enExample)
CA (2) CA2940445C (enExample)
DK (1) DK3117216T3 (enExample)
FI (1) FI3117216T3 (enExample)
RU (1) RU2720148C9 (enExample)
WO (1) WO2015137870A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3312749T3 (pl) 2012-03-05 2024-10-07 Oy Arctic Partners Ab Metody i aparaty do prognozowania ryzyka raka gruczołu krokowego i objętości gruczołu krokowego
PE20170298A1 (es) 2014-03-28 2017-04-18 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico del cancer de prostata
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
JP6749337B2 (ja) 2015-03-27 2020-09-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 前立腺抗原標準およびその使用
US11479878B2 (en) 2016-03-16 2022-10-25 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
ES2688213T3 (es) * 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos
FI3577237T3 (fi) * 2017-02-01 2023-08-29 Phadia Ab Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia
EP3577215A4 (en) * 2017-02-03 2020-12-30 The Johns Hopkins University USE OF MINI-CANCERS FOR PERSONALIZED ANTI-CANCER DRUG PROTOCOLS
RU2664706C2 (ru) * 2017-06-02 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ прогнозирования клинического статуса рака предстательной железы
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
WO2020205204A1 (en) * 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
EP4609409A1 (en) * 2022-10-27 2025-09-03 Myome, Inc. Approach for early detection of disease combining multiple data sources
WO2024092136A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center Machine learning modeling for inpatient prediction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080025489A (ko) * 2006-09-18 2008-03-21 충북대학교 산학협력단 종양표시인자 검출용 바이오센서
WO2012092336A2 (en) * 2010-12-28 2012-07-05 Caris Mpi, Inc. Molecular profiling for cancer
US20130196868A1 (en) * 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
US20050277137A1 (en) 2003-08-15 2005-12-15 University Of Pittsburgh Diagnostic multimarker serological profiling
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
CA2750062A1 (en) 2009-01-19 2010-07-22 Katrin Stedronsky Diagnostic assays for prostate cancer using psp94 and psa biomarkers
US20120121618A1 (en) 2009-02-12 2012-05-17 Dana-Farber Cancer Institute, Inc. Predicting And Treating Prostate Cancer
EP2407555A1 (en) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Methods and kits for the diagnosis of prostate cancer
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
EP3327146A1 (en) 2012-11-20 2018-05-30 Phadia AB Method for indicating a presence or non-presence of aggressive prostate cancer
RU2669809C2 (ru) * 2012-11-20 2018-10-16 Пхадиа Аб Способ прогноза для индивидуумов с раком предстательной железы

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080025489A (ko) * 2006-09-18 2008-03-21 충북대학교 산학협력단 종양표시인자 검출용 바이오센서
WO2012092336A2 (en) * 2010-12-28 2012-07-05 Caris Mpi, Inc. Molecular profiling for cancer
US20130196868A1 (en) * 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PIIRONEN T. et al. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing, Clin Chem., 2001, Apr; 47(4):703-11. *
PIIRONEN T. et al. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing, Clin Chem., 2001, Apr; 47(4):703-11. ЧИССОВ В.И. под ред., Онкология: национальное руководство, М.: ГЭОТАР-Медиа, 2008, с. 788-798. *
ЧИССОВ В.И. под ред., Онкология: национальное руководство, М.: ГЭОТАР-Медиа, 2008, с. 788-798. *

Also Published As

Publication number Publication date
AU2021232712A1 (en) 2021-10-14
RU2016139491A (ru) 2018-04-16
WO2015137870A1 (en) 2015-09-17
JP6625061B2 (ja) 2019-12-25
AU2021232712B2 (en) 2024-10-03
US20170108501A1 (en) 2017-04-20
EP4220170A3 (en) 2023-12-13
AU2015230017B2 (en) 2021-06-17
EP4220170A2 (en) 2023-08-02
JP2017508970A (ja) 2017-03-30
CA2940445A1 (en) 2015-09-17
RU2720148C2 (ru) 2020-04-24
EP3117216B1 (en) 2023-01-11
FI3117216T3 (fi) 2023-04-27
HK1231559A1 (en) 2017-12-22
AU2015230017A1 (en) 2016-09-08
CA2940445C (en) 2021-11-30
EP3117216A1 (en) 2017-01-18
US10451626B2 (en) 2019-10-22
DK3117216T3 (da) 2023-04-03
CA3134289A1 (en) 2015-09-17
RU2016139491A3 (enExample) 2018-10-15

Similar Documents

Publication Publication Date Title
RU2720148C9 (ru) Способ обнаружения солидной злокачественной опухоли
US10431326B2 (en) Method for indicating a presence or non-presence of aggressive prostate cancer
US20200010912A1 (en) Prognostic method for individuals with prostate cancer
JP2015524052A (ja) 前立腺癌の存在または不存在の提示方法
JP2022179483A (ja) 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
CN105051206B (zh) 用于指示侵袭性前列腺癌的存在或不存在的方法
HK1231559B (en) Method for detecting a solid tumor cancer
HK1215594B (en) Method for indicating a presence or non-presence of aggressive prostate cancer

Legal Events

Date Code Title Description
TH4A Reissue of patent specification